Spruce Biosciences, Inc. Financial and Nonfinancial Liabilities, Fair Value Disclosure
Spruce Biosciences, Inc. (SPRB) had Financial and Nonfinancial Liabilities, Fair Value Disclosure of $0 as of 2025-12-31, per its 10-Q filed 2026-08-12.
Financial Statements › Notes
us-gaap:LiabilitiesFairValueDisclosure · last filed 2026-08-12
- 2025-12-31: Financial and Nonfinancial Liabilities, Fair Value Disclosure $0.00.
- 2024-12-31: Financial and Nonfinancial Liabilities, Fair Value Disclosure $0.00.
| Period end | Financial and Nonfinancial Liabilities, Fair Value Disclosure |
|---|---|
| 2025-12-31 | $0.00 10-Q · filed 2026-08-12 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |